<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00814710</url>
  </required_header>
  <id_info>
    <org_study_id>111188</org_study_id>
    <nct_id>NCT00814710</nct_id>
  </id_info>
  <brief_title>Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 10 Weeks of Age</brief_title>
  <official_title>Primary Vaccination Course in Healthy Children Receiving the Pneumococcal Vaccine GSK 1024850A Co-administered With Tritanrix™-HepB/Hib at 6, 10 and 14 Weeks of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the immunogenicity in terms of antibody response and
      the safety/reactogenicity in terms of solicited and unsolicited symptoms and serious adverse
      events following primary vaccination of Indian infants with pneumococcal conjugate vaccine
      GSK1024850A co-administered with a diphtheria, tetanus, whole cell pertussis (DTPw)-combined
      vaccine during the first 4 months of life. The study will be conducted in India.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Concentrations of Antibodies Against Vaccine Pneumococcal Serotypes</measure>
    <time_frame>One month after primary immunization (month 3)</time_frame>
    <description>Concentrations were expressed as Geometric Mean Concentrations (GMCs) in microgram per milliliter (µg/mL).
Pneumococcal serotypes included 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration of Antibody Against Protein D (PD)</measure>
    <time_frame>One month after primary immunization (month 3)</time_frame>
    <description>Concentrations were expressed as GMCs GSK's 22F-inhibition in enzyme-linked-immunosorbent assay (ELISA) units per milliliter (EL.U/mL).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Opsonophagocytic Activity Against Pneumococcal Serotypes</measure>
    <time_frame>One month after primary immunization (month 3)</time_frame>
    <description>Vaccine pneumococcal serotypes included 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F.
Cross-reactive pneumococcal serotypes included 6A and 19A.
Opsonophagocytic activity was defined as the dilution of serum (opsonic titer) able to sustain 50% killing of live pneumococci under the assay conditions. The cut-off of the assay was an opsonic titer equal to or greater than 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Antibody Concentrations Against Pneumococcal Serotypes Equal to or Above Cut-off Value</measure>
    <time_frame>One month after primary immunization</time_frame>
    <description>Vaccine pneumococcal serotypes included 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F. Cross-reactive pneumococcal serotypes included 6A and 19A.
The cut-off was defined as 0.20 microgram per milliliter (µg/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentrations of Antibodies Against Pneumococcal Cross-reactive Serotypes</measure>
    <time_frame>One month after primary immunization (month 3)</time_frame>
    <description>Concentrations were expressed as GMCs in µg/mL. Pneumococcal cross-reactive serotypes included 6A and 19A.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Seropositive for Pneumococcal Serotypes</measure>
    <time_frame>One month after primary immunization (month 3)</time_frame>
    <description>Vaccine pneumococcal serotypes included 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F. Cross-reactive pneumococcal serotypes included 6A and 19A.
Seropositivity was defined as a titer equal to or greater than 0.05 µg/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Seropositive for Protein D (PD)</measure>
    <time_frame>One month after primary immunization (month 3)</time_frame>
    <description>Seropositivity for PD was defined greater than or equal to 100 EL.U/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of Antibody Against Polyribosyl-ribitol Phosphate (PRP)</measure>
    <time_frame>One month after primary immunization (month 3)</time_frame>
    <description>Concentration is expressed as GMC in µg/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of Antibodies Against Diphteria (Anti-DT) and Tetanus (Anti-TT)</measure>
    <time_frame>One month after primary immunization (month 3)</time_frame>
    <description>Concentrations were expressed as GMCs in international units per milliliter (IU/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of Antibody Against Bordetella Pertussis (B. Pertussis)</measure>
    <time_frame>One month after primary immunization (month 3)</time_frame>
    <description>Concentration was expressed as GMC in EL.U/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of Antibody Against Hepatitis B (Anti-HBs)</measure>
    <time_frame>One month after primary immunization (month 3)</time_frame>
    <description>Concentration was expressed as GMC in milli international units per milliliter (mIU/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Seropostive for B. Pertussis</measure>
    <time_frame>One month after primary immunization (month 3)</time_frame>
    <description>Seropositivity was defined as and antibody concentration equal to or greater than 15 EL.U/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seroprotected Subjects (Anti-DT, Anti-TT, Anti-PRP, Anti-HBs)</measure>
    <time_frame>One month after primary immunization (month 3)</time_frame>
    <description>Seroprotection was defined as:
Anti-DT antibody concentration equal to or greater than 0.1 IU/mL. Anti-TT antibody concentration equal to or greater than 0.1 IU/mL. Anti-PRP antibody concentration equal to or greater than 0.15 µg/mL Anti-HBs antibody concentration greater than or equal to 10 mIU/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seroprotected Subjects (Anti-PRP Above the Cut-off of 1.0 µg/mL)</measure>
    <time_frame>One month after primary immunization (month 3)</time_frame>
    <description>Anti-PRP antibody concentration equal to or greater than 1.0 µg/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Solicited Local and General Symptoms</measure>
    <time_frame>Within 4 days (day 0-3) after vaccination</time_frame>
    <description>Solicited local symptoms included pain, redness and swelling. Solicited general symptoms included drowsiness, fever (equal to or above 38 degrees Celsius and above 39 degrees Celsius), irritability and loss of appetite.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Unsolicited Adverse Events (AEs)</measure>
    <time_frame>Within 31 days (day 0-30) after vaccination</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Serious Adverse Events (SAEs)</measure>
    <time_frame>Following first vaccination (Month 0) throughout the entire study period (month 3)</time_frame>
    <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">360</enrollment>
  <condition>Infections, Streptococcal</condition>
  <arm_group>
    <arm_group_label>Synflorix &amp; Tritanrix-HebB/Hib Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received SynflorixTM (GSK1024850A) intramuscularly in the right thigh co-administered with TritanrixTM-HepB/Hib intramuscularly in the left thigh at 6-10-14 weeks of age (=study month 0, 1, 2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hiberix group &amp; Tritanrix-HebB Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects received HiberixTM intramuscularly in the right thigh co-administered with TritanrixTM-HepB intramuscularly in the left thigh at 6-10-14 weeks of age (=study month 0, 1, 2)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pneumococcal conjugate vaccine GSK1024850A</intervention_name>
    <description>Intramuscular injection, 3 doses</description>
    <arm_group_label>Synflorix &amp; Tritanrix-HebB/Hib Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Tritanrix-HepB/Hib</intervention_name>
    <description>Intramuscular injection, 3 doses</description>
    <arm_group_label>Synflorix &amp; Tritanrix-HebB/Hib Group</arm_group_label>
    <other_name>DTPw-HBV/Hib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Hiberix</intervention_name>
    <description>Intramuscular injection, 3 doses</description>
    <arm_group_label>Hiberix group &amp; Tritanrix-HebB Group</arm_group_label>
    <other_name>Hib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Tritanrix-HepB</intervention_name>
    <description>Intramuscular injection, 3 doses</description>
    <arm_group_label>Hiberix group &amp; Tritanrix-HebB Group</arm_group_label>
    <other_name>DTPw-HBV</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects between, and including 6-10 weeks of age at the time of the
             first vaccination.

          -  Subjects for whom the investigator believes that their parent(s)/guardian(s) can and
             will comply with the requirements of the protocol.

          -  Written or oral, signed or thumb-printed informed consent obtained from the
             parent(s)/guardian(s) of the child/ward. Where parent(s)/guardian(s) are illiterate,
             the consent form will be countersigned by a witness.

          -  Free of any known or suspected health problems (as established by medical history and
             clinical examination before entering into the study).

        Exclusion Criteria:

          -  Use of any investigational or non-registered product (drug or vaccine) other than the
             study vaccines within 30 days preceding the first dose of the study vaccines, or
             planned use during the study period.

          -  Concurrently participating in another clinical study, at any time during the study
             period, in which the subject has been or will be exposed to an investigational or a
             non-investigational product (pharmaceutical product or device).

          -  Chronic administration (defined as more than 14 days) of immunosuppressants or other
             immune-modifying drugs since birth.

          -  A family history of congenital or hereditary immunodeficiency.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition based on
             medical history and physical examination.

          -  Administration of immunoglobulins and/or any blood products since birth or planned
             administration during the study period (with the exception of hepatitis B
             immunoglobulins at birth).

          -  Previous vaccination against diphtheria, tetanus, pertussis, hepatitis B, Haemophilus
             influenzae type b and/or Streptococcus pneumoniae (with the exception of hepatitis B
             vaccination at birth or at least 30 days before the subject's first study visit).

          -  History of, or intercurrent, diphtheria, tetanus, pertussis, hepatitis B,
             Streptococcus and Haemophilus influenzae type b disease.

          -  History of allergic disease or reactions likely to be exacerbated by any component of
             the vaccines.

          -  History of any neurological disorders or seizures.

          -  Major congenital defects or serious chronic illness.

          -  Acute disease at the time of enrolment.

          -  Babies for which birth weight is &lt; 2 kilogram.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Weeks</minimum_age>
    <maximum_age>10 Weeks</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kolkata</city>
        <zip>700073</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ludhiana</city>
        <zip>141 008</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pune</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vellore</city>
        <zip>632004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <reference>
    <citation>Lalwani S, Chatterjee S, Chhatwal J, Verghese VP, Mehta S, Shafi F, Borys D, Moreira M, Schuerman L. Immunogenicity, safety, and reactogenicity of the 10-valent pneumococcal non-typeable Hemophilus influenzae protein D conjugate vaccine (PHiD-CV) when co-administered with the DTPw-HBV/Hib vaccine in Indian infants: a single-blind, randomized, controlled study. Hum Vaccin Immunother. 2012 May;8(5):612-22. doi: 10.4161/hv.19287. Epub 2012 May 1.</citation>
    <PMID>22634448</PMID>
  </reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 23, 2008</study_first_submitted>
  <study_first_submitted_qc>December 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 25, 2008</study_first_posted>
  <results_first_submitted>October 21, 2010</results_first_submitted>
  <results_first_submitted_qc>October 21, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 29, 2010</results_first_posted>
  <last_update_submitted>October 6, 2016</last_update_submitted>
  <last_update_submitted_qc>October 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pneumococcal disease</keyword>
  <keyword>Pneumococcal vaccine</keyword>
  <keyword>Safety</keyword>
  <keyword>Primary vaccination</keyword>
  <keyword>Immunogenicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Streptococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>111188</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111188</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111188</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111188</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111188</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111188</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111188</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Synflorix and Tritanrix-HepB/Hib Group</title>
          <description>Subjects received SynflorixTM (GSK1024850A) intramuscularly in the right thigh co-administered with TritanrixTM-HepB/Hib intramuscularly in the left thigh at 6-10-14 weeks of age (=study month 0, 1, 2)</description>
        </group>
        <group group_id="P2">
          <title>Hiberix Group and Tritanrix-HepB Group</title>
          <description>Subjects received HiberixTM intramuscularly in the right thigh co-administered with TritanrixTM-HepB intramuscularly in the left thigh at 6-10-14 weeks of age (=study month 0, 1, 2)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="240"/>
                <participants group_id="P2" count="120"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="232"/>
                <participants group_id="P2" count="117"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Synflorix and Tritanrix-HepB/Hib Group</title>
          <description>Subjects received SynflorixTM (GSK1024850A) intramuscularly in the right thigh co-administered with TritanrixTM-HepB/Hib intramuscularly in the left thigh at 6-10-14 weeks of age (=study month 0, 1, 2)</description>
        </group>
        <group group_id="B2">
          <title>Hiberix Group and Tritanrix-HepB Group</title>
          <description>Subjects received HiberixTM intramuscularly in the right thigh co-administered with TritanrixTM-HepB intramuscularly in the left thigh at 6-10-14 weeks of age (=study month 0, 1, 2)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="240"/>
            <count group_id="B2" value="120"/>
            <count group_id="B3" value="360"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.7" spread="1.08"/>
                    <measurement group_id="B2" value="6.7" spread="1.05"/>
                    <measurement group_id="B3" value="6.7" spread="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="109"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="131"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Concentrations of Antibodies Against Vaccine Pneumococcal Serotypes</title>
        <description>Concentrations were expressed as Geometric Mean Concentrations (GMCs) in microgram per milliliter (µg/mL).
Pneumococcal serotypes included 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F.</description>
        <time_frame>One month after primary immunization (month 3)</time_frame>
        <population>Analysis was performed on the According-to-Protocol cohort for immunogenicity, which included all evaluable subjects with available immunogenicity data.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix and Tritanrix-HepB/Hib Group</title>
            <description>Subjects received SynflorixTM (GSK1024850A) intramuscularly in the right thigh co-administered with TritanrixTM-HepB/Hib intramuscularly in the left thigh at 6-10-14 weeks of age (=study month 0, 1, 2)</description>
          </group>
          <group group_id="O2">
            <title>Hiberix Group and Tritanrix-HepB Group</title>
            <description>Subjects received HiberixTM intramuscularly in the right thigh co-administered with TritanrixTM-HepB intramuscularly in the left thigh at 6-10-14 weeks of age (=study month 0, 1, 2)</description>
          </group>
        </group_list>
        <measure>
          <title>Concentrations of Antibodies Against Vaccine Pneumococcal Serotypes</title>
          <description>Concentrations were expressed as Geometric Mean Concentrations (GMCs) in microgram per milliliter (µg/mL).
Pneumococcal serotypes included 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F.</description>
          <population>Analysis was performed on the According-to-Protocol cohort for immunogenicity, which included all evaluable subjects with available immunogenicity data.</population>
          <units>µg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="229"/>
                <count group_id="O2" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.27" lower_limit="2.91" upper_limit="3.67"/>
                    <measurement group_id="O2" value="0.03" lower_limit="0.03" upper_limit="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.80" lower_limit="3.33" upper_limit="4.33"/>
                    <measurement group_id="O2" value="0.04" lower_limit="0.03" upper_limit="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.17" lower_limit="3.72" upper_limit="4.67"/>
                    <measurement group_id="O2" value="0.05" lower_limit="0.04" upper_limit="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.71" lower_limit="0.59" upper_limit="0.86"/>
                    <measurement group_id="O2" value="0.05" lower_limit="0.04" upper_limit="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.87" lower_limit="3.47" upper_limit="4.31"/>
                    <measurement group_id="O2" value="0.06" lower_limit="0.05" upper_limit="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.21" lower_limit="3.71" upper_limit="4.78"/>
                    <measurement group_id="O2" value="0.06" lower_limit="0.05" upper_limit="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.21" lower_limit="4.51" upper_limit="6.01"/>
                    <measurement group_id="O2" value="0.26" lower_limit="0.20" upper_limit="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.23" lower_limit="12.96" upper_limit="17.90"/>
                    <measurement group_id="O2" value="0.07" lower_limit="0.05" upper_limit="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.78" lower_limit="10.26" upper_limit="13.53"/>
                    <measurement group_id="O2" value="0.12" lower_limit="0.10" upper_limit="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.18" lower_limit="0.98" upper_limit="1.42"/>
                    <measurement group_id="O2" value="0.05" lower_limit="0.04" upper_limit="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Opsonophagocytic Activity Against Pneumococcal Serotypes</title>
        <description>Vaccine pneumococcal serotypes included 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F.
Cross-reactive pneumococcal serotypes included 6A and 19A.
Opsonophagocytic activity was defined as the dilution of serum (opsonic titer) able to sustain 50% killing of live pneumococci under the assay conditions. The cut-off of the assay was an opsonic titer equal to or greater than 8.</description>
        <time_frame>One month after primary immunization (month 3)</time_frame>
        <population>Analysis was performed on the According-to-Protocol cohort for immunogenicity, which included all evaluable subjects with available immunogenicity data.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix and Tritanrix-HepB/Hib Group</title>
            <description>Subjects received SynflorixTM (GSK1024850A) intramuscularly in the right thigh co-administered with TritanrixTM-HepB/Hib intramuscularly in the left thigh at 6-10-14 weeks of age (=study month 0, 1, 2)</description>
          </group>
          <group group_id="O2">
            <title>Hiberix Group and Tritanrix-HepB Group</title>
            <description>Subjects received HiberixTM intramuscularly in the right thigh co-administered with TritanrixTM-HepB intramuscularly in the left thigh at 6-10-14 weeks of age (=study month 0, 1, 2)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Opsonophagocytic Activity Against Pneumococcal Serotypes</title>
          <description>Vaccine pneumococcal serotypes included 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F.
Cross-reactive pneumococcal serotypes included 6A and 19A.
Opsonophagocytic activity was defined as the dilution of serum (opsonic titer) able to sustain 50% killing of live pneumococci under the assay conditions. The cut-off of the assay was an opsonic titer equal to or greater than 8.</description>
          <population>Analysis was performed on the According-to-Protocol cohort for immunogenicity, which included all evaluable subjects with available immunogenicity data.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="116"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Opsono-1 (N=116; 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Opsono-4 (N=116; 55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Opsono-5 (N= 116; 56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Opsono-6B (N=116; 54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Opsono-7F (N=116; 53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Opsono-9V (N=115; 56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Opsono-14 (N=115; 56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Opsono-18C (N=115; 55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Opsono-19F (N=116; 56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Opsono-23F (N=116; 54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Opsono-6A (N=110;57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Opsono-19A (N=109;57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Antibody Concentrations Against Pneumococcal Serotypes Equal to or Above Cut-off Value</title>
        <description>Vaccine pneumococcal serotypes included 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F. Cross-reactive pneumococcal serotypes included 6A and 19A.
The cut-off was defined as 0.20 microgram per milliliter (µg/mL).</description>
        <time_frame>One month after primary immunization</time_frame>
        <population>Analysis was performed on the According-to-Protocol cohort for immunogenicity, which included all evaluable subjects with available immunogenicity data.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix and Tritanrix-HepB/Hib Group</title>
            <description>Subjects received SynflorixTM (GSK1024850A) intramuscularly in the right thigh co-administered with TritanrixTM-HepB/Hib intramuscularly in the left thigh at 6-10-14 weeks of age (=study month 0, 1, 2)</description>
          </group>
          <group group_id="O2">
            <title>Hiberix Group and Tritanrix-HepB Group</title>
            <description>Subjects received HiberixTM intramuscularly in the right thigh co-administered with TritanrixTM-HepB intramuscularly in the left thigh at 6-10-14 weeks of age (=study month 0, 1, 2)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Antibody Concentrations Against Pneumococcal Serotypes Equal to or Above Cut-off Value</title>
          <description>Vaccine pneumococcal serotypes included 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F. Cross-reactive pneumococcal serotypes included 6A and 19A.
The cut-off was defined as 0.20 microgram per milliliter (µg/mL).</description>
          <population>Analysis was performed on the According-to-Protocol cohort for immunogenicity, which included all evaluable subjects with available immunogenicity data.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="229"/>
                <count group_id="O2" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="228"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="225"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="226"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="178"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="228"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="227"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="229"/>
                    <measurement group_id="O2" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="227"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="227"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="205"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-6A (N=229;115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-19A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concentrations of Antibodies Against Pneumococcal Cross-reactive Serotypes</title>
        <description>Concentrations were expressed as GMCs in µg/mL. Pneumococcal cross-reactive serotypes included 6A and 19A.</description>
        <time_frame>One month after primary immunization (month 3)</time_frame>
        <population>Analysis was performed on the According-to-Protocol cohort for immunogenicity, which included all evaluable subjects with available immunogenicity data.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix and Tritanrix-HepB/Hib Group</title>
            <description>Subjects received SynflorixTM (GSK1024850A) intramuscularly in the right thigh co-administered with TritanrixTM-HepB/Hib intramuscularly in the left thigh at 6-10-14 weeks of age (=study month 0, 1, 2)</description>
          </group>
          <group group_id="O2">
            <title>Hiberix Group and Tritanrix-HepB Group</title>
            <description>Subjects received HiberixTM intramuscularly in the right thigh co-administered with TritanrixTM-HepB intramuscularly in the left thigh at 6-10-14 weeks of age (=study month 0, 1, 2)</description>
          </group>
        </group_list>
        <measure>
          <title>Concentrations of Antibodies Against Pneumococcal Cross-reactive Serotypes</title>
          <description>Concentrations were expressed as GMCs in µg/mL. Pneumococcal cross-reactive serotypes included 6A and 19A.</description>
          <population>Analysis was performed on the According-to-Protocol cohort for immunogenicity, which included all evaluable subjects with available immunogenicity data.</population>
          <units>µg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="229"/>
                <count group_id="O2" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-6A (N=229;115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" lower_limit="0.13" upper_limit="0.18"/>
                    <measurement group_id="O2" value="0.06" lower_limit="0.05" upper_limit="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-19A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.33" lower_limit="0.27" upper_limit="0.39"/>
                    <measurement group_id="O2" value="0.08" lower_limit="0.06" upper_limit="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Seropositive for Pneumococcal Serotypes</title>
        <description>Vaccine pneumococcal serotypes included 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F. Cross-reactive pneumococcal serotypes included 6A and 19A.
Seropositivity was defined as a titer equal to or greater than 0.05 µg/mL</description>
        <time_frame>One month after primary immunization (month 3)</time_frame>
        <population>Analysis was performed on the According-to-Protocol cohort for immunogenicity, which included all evaluable subjects with available immunogenicity data.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix and Tritanrix-HepB/Hib Group</title>
            <description>Subjects received SynflorixTM (GSK1024850A) intramuscularly in the right thigh co-administered with TritanrixTM-HepB/Hib intramuscularly in the left thigh at 6-10-14 weeks of age (=study month 0, 1, 2)</description>
          </group>
          <group group_id="O2">
            <title>Hiberix Group and Tritanrix-HepB Group</title>
            <description>Subjects received HiberixTM intramuscularly in the right thigh co-administered with TritanrixTM-HepB intramuscularly in the left thigh at 6-10-14 weeks of age (=study month 0, 1, 2)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Seropositive for Pneumococcal Serotypes</title>
          <description>Vaccine pneumococcal serotypes included 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F. Cross-reactive pneumococcal serotypes included 6A and 19A.
Seropositivity was defined as a titer equal to or greater than 0.05 µg/mL</description>
          <population>Analysis was performed on the According-to-Protocol cohort for immunogenicity, which included all evaluable subjects with available immunogenicity data.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="229"/>
                <count group_id="O2" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="228"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="228"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="229"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="215"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="229"/>
                    <measurement group_id="O2" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="228"/>
                    <measurement group_id="O2" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="229"/>
                    <measurement group_id="O2" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="227"/>
                    <measurement group_id="O2" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="229"/>
                    <measurement group_id="O2" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="220"/>
                    <measurement group_id="O2" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-6A (N=229;115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="188"/>
                    <measurement group_id="O2" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-19A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="207"/>
                    <measurement group_id="O2" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Seropositive for Protein D (PD)</title>
        <description>Seropositivity for PD was defined greater than or equal to 100 EL.U/mL.</description>
        <time_frame>One month after primary immunization (month 3)</time_frame>
        <population>Analysis was performed on the According-to-Protocol cohort for immunogenicity, which included all evaluable subjects with available immunogenicity data.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix and Tritanrix-HepB/Hib Group</title>
            <description>Subjects received SynflorixTM (GSK1024850A) intramuscularly in the right thigh co-administered with TritanrixTM-HepB/Hib intramuscularly in the left thigh at 6-10-14 weeks of age (=study month 0, 1, 2)</description>
          </group>
          <group group_id="O2">
            <title>Hiberix Group and Tritanrix-HepB Group</title>
            <description>Subjects received HiberixTM intramuscularly in the right thigh co-administered with TritanrixTM-HepB intramuscularly in the left thigh at 6-10-14 weeks of age (=study month 0, 1, 2)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Seropositive for Protein D (PD)</title>
          <description>Seropositivity for PD was defined greater than or equal to 100 EL.U/mL.</description>
          <population>Analysis was performed on the According-to-Protocol cohort for immunogenicity, which included all evaluable subjects with available immunogenicity data.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="226"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concentration of Antibody Against Polyribosyl-ribitol Phosphate (PRP)</title>
        <description>Concentration is expressed as GMC in µg/mL.</description>
        <time_frame>One month after primary immunization (month 3)</time_frame>
        <population>Analysis was performed on the According-to-Protocol cohort for immunogenicity, which included all evaluable subjects with available immunogenicity data.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix and Tritanrix-HepB/Hib Group</title>
            <description>Subjects received SynflorixTM (GSK1024850A) intramuscularly in the right thigh co-administered with TritanrixTM-HepB/Hib intramuscularly in the left thigh at 6-10-14 weeks of age (=study month 0, 1, 2)</description>
          </group>
          <group group_id="O2">
            <title>Hiberix Group and Tritanrix-HepB Group</title>
            <description>Subjects received HiberixTM intramuscularly in the right thigh co-administered with TritanrixTM-HepB intramuscularly in the left thigh at 6-10-14 weeks of age (=study month 0, 1, 2)</description>
          </group>
        </group_list>
        <measure>
          <title>Concentration of Antibody Against Polyribosyl-ribitol Phosphate (PRP)</title>
          <description>Concentration is expressed as GMC in µg/mL.</description>
          <population>Analysis was performed on the According-to-Protocol cohort for immunogenicity, which included all evaluable subjects with available immunogenicity data.</population>
          <units>µg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.367" lower_limit="26.417" upper_limit="37.246"/>
                    <measurement group_id="O2" value="34.415" lower_limit="26.847" upper_limit="44.116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concentration of Antibodies Against Diphteria (Anti-DT) and Tetanus (Anti-TT)</title>
        <description>Concentrations were expressed as GMCs in international units per milliliter (IU/mL).</description>
        <time_frame>One month after primary immunization (month 3)</time_frame>
        <population>Analysis was performed on the According-to-Protocol cohort for immunogenicity, which included all evaluable subjects with available immunogenicity data.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix and Tritanrix-HepB/Hib Group</title>
            <description>Subjects received SynflorixTM (GSK1024850A) intramuscularly in the right thigh co-administered with TritanrixTM-HepB/Hib intramuscularly in the left thigh at 6-10-14 weeks of age (=study month 0, 1, 2)</description>
          </group>
          <group group_id="O2">
            <title>Hiberix Group and Tritanrix-HepB Group</title>
            <description>Subjects received HiberixTM intramuscularly in the right thigh co-administered with TritanrixTM-HepB intramuscularly in the left thigh at 6-10-14 weeks of age (=study month 0, 1, 2)</description>
          </group>
        </group_list>
        <measure>
          <title>Concentration of Antibodies Against Diphteria (Anti-DT) and Tetanus (Anti-TT)</title>
          <description>Concentrations were expressed as GMCs in international units per milliliter (IU/mL).</description>
          <population>Analysis was performed on the According-to-Protocol cohort for immunogenicity, which included all evaluable subjects with available immunogenicity data.</population>
          <units>IU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-DT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.580" lower_limit="2.146" upper_limit="3.102"/>
                    <measurement group_id="O2" value="2.065" lower_limit="1.736" upper_limit="2.457"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-TT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.726" lower_limit="3.182" upper_limit="4.363"/>
                    <measurement group_id="O2" value="1.542" lower_limit="1.316" upper_limit="1.807"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concentration of Antibody Against Bordetella Pertussis (B. Pertussis)</title>
        <description>Concentration was expressed as GMC in EL.U/mL.</description>
        <time_frame>One month after primary immunization (month 3)</time_frame>
        <population>Analysis was performed on the According-to-Protocol cohort for immunogenicity, which included all evaluable subjects with available immunogenicity data.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix and Tritanrix-HepB/Hib Group</title>
            <description>Subjects received SynflorixTM (GSK1024850A) intramuscularly in the right thigh co-administered with TritanrixTM-HepB/Hib intramuscularly in the left thigh at 6-10-14 weeks of age (=study month 0, 1, 2)</description>
          </group>
          <group group_id="O2">
            <title>Hiberix Group and Tritanrix-HepB Group</title>
            <description>Subjects received HiberixTM intramuscularly in the right thigh co-administered with TritanrixTM-HepB intramuscularly in the left thigh at 6-10-14 weeks of age (=study month 0, 1, 2)</description>
          </group>
        </group_list>
        <measure>
          <title>Concentration of Antibody Against Bordetella Pertussis (B. Pertussis)</title>
          <description>Concentration was expressed as GMC in EL.U/mL.</description>
          <population>Analysis was performed on the According-to-Protocol cohort for immunogenicity, which included all evaluable subjects with available immunogenicity data.</population>
          <units>EL.U/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.3" lower_limit="80.3" upper_limit="101.6"/>
                    <measurement group_id="O2" value="114.5" lower_limit="101.2" upper_limit="129.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concentration of Antibody Against Hepatitis B (Anti-HBs)</title>
        <description>Concentration was expressed as GMC in milli international units per milliliter (mIU/mL).</description>
        <time_frame>One month after primary immunization (month 3)</time_frame>
        <population>Analysis was performed on the According-to-Protocol cohort for immunogenicity, which included all evaluable subjects with available immunogenicity data.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix and Tritanrix-HepB/Hib Group</title>
            <description>Subjects received SynflorixTM (GSK1024850A) intramuscularly in the right thigh co-administered with TritanrixTM-HepB/Hib intramuscularly in the left thigh at 6-10-14 weeks of age (=study month 0, 1, 2)</description>
          </group>
          <group group_id="O2">
            <title>Hiberix Group and Tritanrix-HepB Group</title>
            <description>Subjects received HiberixTM intramuscularly in the right thigh co-administered with TritanrixTM-HepB intramuscularly in the left thigh at 6-10-14 weeks of age (=study month 0, 1, 2)</description>
          </group>
        </group_list>
        <measure>
          <title>Concentration of Antibody Against Hepatitis B (Anti-HBs)</title>
          <description>Concentration was expressed as GMC in milli international units per milliliter (mIU/mL).</description>
          <population>Analysis was performed on the According-to-Protocol cohort for immunogenicity, which included all evaluable subjects with available immunogenicity data.</population>
          <units>mIU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1970.5" lower_limit="1614.9" upper_limit="2404.5"/>
                    <measurement group_id="O2" value="1378.2" lower_limit="1115.6" upper_limit="1702.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Seropostive for B. Pertussis</title>
        <description>Seropositivity was defined as and antibody concentration equal to or greater than 15 EL.U/mL.</description>
        <time_frame>One month after primary immunization (month 3)</time_frame>
        <population>Analysis was performed on the According-to-Protocol cohort for immunogenicity, which included all evaluable subjects with available immunogenicity data.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix and Tritanrix-HepB/Hib Group</title>
            <description>Subjects received SynflorixTM (GSK1024850A) intramuscularly in the right thigh co-administered with TritanrixTM-HepB/Hib intramuscularly in the left thigh at 6-10-14 weeks of age (=study month 0, 1, 2)</description>
          </group>
          <group group_id="O2">
            <title>Hiberix Group and Tritanrix-HepB Group</title>
            <description>Subjects received HiberixTM intramuscularly in the right thigh co-administered with TritanrixTM-HepB intramuscularly in the left thigh at 6-10-14 weeks of age (=study month 0, 1, 2)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Seropostive for B. Pertussis</title>
          <description>Seropositivity was defined as and antibody concentration equal to or greater than 15 EL.U/mL.</description>
          <population>Analysis was performed on the According-to-Protocol cohort for immunogenicity, which included all evaluable subjects with available immunogenicity data.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113"/>
                    <measurement group_id="O2" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seroprotected Subjects (Anti-DT, Anti-TT, Anti-PRP, Anti-HBs)</title>
        <description>Seroprotection was defined as:
Anti-DT antibody concentration equal to or greater than 0.1 IU/mL. Anti-TT antibody concentration equal to or greater than 0.1 IU/mL. Anti-PRP antibody concentration equal to or greater than 0.15 µg/mL Anti-HBs antibody concentration greater than or equal to 10 mIU/mL.</description>
        <time_frame>One month after primary immunization (month 3)</time_frame>
        <population>Analysis was performed on the According-to-Protocol cohort for immunogenicity, which included all evaluable subjects with available immunogenicity data.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix and Tritanrix-HepB/Hib Group</title>
            <description>Subjects received SynflorixTM (GSK1024850A) intramuscularly in the right thigh co-administered with TritanrixTM-HepB/Hib intramuscularly in the left thigh at 6-10-14 weeks of age (=study month 0, 1, 2)</description>
          </group>
          <group group_id="O2">
            <title>Hiberix Group and Tritanrix-HepB Group</title>
            <description>Subjects received HiberixTM intramuscularly in the right thigh co-administered with TritanrixTM-HepB intramuscularly in the left thigh at 6-10-14 weeks of age (=study month 0, 1, 2)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroprotected Subjects (Anti-DT, Anti-TT, Anti-PRP, Anti-HBs)</title>
          <description>Seroprotection was defined as:
Anti-DT antibody concentration equal to or greater than 0.1 IU/mL. Anti-TT antibody concentration equal to or greater than 0.1 IU/mL. Anti-PRP antibody concentration equal to or greater than 0.15 µg/mL Anti-HBs antibody concentration greater than or equal to 10 mIU/mL.</description>
          <population>Analysis was performed on the According-to-Protocol cohort for immunogenicity, which included all evaluable subjects with available immunogenicity data.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-DT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113"/>
                    <measurement group_id="O2" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-TT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113"/>
                    <measurement group_id="O2" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PRP 0.15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113"/>
                    <measurement group_id="O2" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HBs (N=92,89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                    <measurement group_id="O2" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Concentration of Antibody Against Protein D (PD)</title>
        <description>Concentrations were expressed as GMCs GSK’s 22F-inhibition in enzyme-linked-immunosorbent assay (ELISA) units per milliliter (EL.U/mL).</description>
        <time_frame>One month after primary immunization (month 3)</time_frame>
        <population>Analysis was performed on the According-to-Protocol cohort for immunogenicity, which included all evaluable subjects with available immunogenicity data.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix and Tritanrix-HepB/Hib Group</title>
            <description>Subjects received SynflorixTM (GSK1024850A) intramuscularly in the right thigh co-administered with TritanrixTM-HepB/Hib intramuscularly in the left thigh at 6-10-14 weeks of age (=study month 0, 1, 2)</description>
          </group>
          <group group_id="O2">
            <title>Hiberix Group and Tritanrix-HepB Group</title>
            <description>Subjects received HiberixTM intramuscularly in the right thigh co-administered with TritanrixTM-HepB intramuscularly in the left thigh at 6-10-14 weeks of age (=study month 0, 1, 2)</description>
          </group>
        </group_list>
        <measure>
          <title>Concentration of Antibody Against Protein D (PD)</title>
          <description>Concentrations were expressed as GMCs GSK’s 22F-inhibition in enzyme-linked-immunosorbent assay (ELISA) units per milliliter (EL.U/mL).</description>
          <population>Analysis was performed on the According-to-Protocol cohort for immunogenicity, which included all evaluable subjects with available immunogenicity data.</population>
          <units>EL.U/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2981.7" lower_limit="2703.0" upper_limit="3289.2"/>
                    <measurement group_id="O2" value="63.9" lower_limit="55.8" upper_limit="73.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seroprotected Subjects (Anti-PRP Above the Cut-off of 1.0 µg/mL)</title>
        <description>Anti-PRP antibody concentration equal to or greater than 1.0 µg/mL.</description>
        <time_frame>One month after primary immunization (month 3)</time_frame>
        <population>Analysis was performed on the According-to-Protocol cohort for immunogenicity, which included all evaluable subjects with available immunogenicity data.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix and Tritanrix-HepB/Hib Group</title>
            <description>Subjects received SynflorixTM (GSK1024850A) intramuscularly in the right thigh co-administered with TritanrixTM-HepB/Hib intramuscularly in the left thigh at 6-10-14 weeks of age (=study month 0, 1, 2)</description>
          </group>
          <group group_id="O2">
            <title>Hiberix Group and Tritanrix-HepB Group</title>
            <description>Subjects received HiberixTM intramuscularly in the right thigh co-administered with TritanrixTM-HepB intramuscularly in the left thigh at 6-10-14 weeks of age (=study month 0, 1, 2)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroprotected Subjects (Anti-PRP Above the Cut-off of 1.0 µg/mL)</title>
          <description>Anti-PRP antibody concentration equal to or greater than 1.0 µg/mL.</description>
          <population>Analysis was performed on the According-to-Protocol cohort for immunogenicity, which included all evaluable subjects with available immunogenicity data.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113"/>
                    <measurement group_id="O2" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Solicited Local and General Symptoms</title>
        <description>Solicited local symptoms included pain, redness and swelling. Solicited general symptoms included drowsiness, fever (equal to or above 38 degrees Celsius and above 39 degrees Celsius), irritability and loss of appetite.</description>
        <time_frame>Within 4 days (day 0-3) after vaccination</time_frame>
        <population>Analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects. However, the total number of subjects analyzed in this Total Vaccinated cohort included all subjects having returned their symptom sheets.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix and Tritanrix-HepB/Hib Group</title>
            <description>Subjects received SynflorixTM (GSK1024850A) intramuscularly in the right thigh co-administered with TritanrixTM-HepB/Hib intramuscularly in the left thigh at 6-10-14 weeks of age (=study month 0, 1, 2)</description>
          </group>
          <group group_id="O2">
            <title>Hiberix Group and Tritanrix-HepB Group</title>
            <description>Subjects received HiberixTM intramuscularly in the right thigh co-administered with TritanrixTM-HepB intramuscularly in the left thigh at 6-10-14 weeks of age (=study month 0, 1, 2)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Solicited Local and General Symptoms</title>
          <description>Solicited local symptoms included pain, redness and swelling. Solicited general symptoms included drowsiness, fever (equal to or above 38 degrees Celsius and above 39 degrees Celsius), irritability and loss of appetite.</description>
          <population>Analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects. However, the total number of subjects analyzed in this Total Vaccinated cohort included all subjects having returned their symptom sheets.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="238"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="209"/>
                    <measurement group_id="O2" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128"/>
                    <measurement group_id="O2" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="166"/>
                    <measurement group_id="O2" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drowsiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever ≥38.0˚C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="182"/>
                    <measurement group_id="O2" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt;39.0˚C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="178"/>
                    <measurement group_id="O2" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss of appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96"/>
                    <measurement group_id="O2" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Unsolicited Adverse Events (AEs)</title>
        <description>An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms</description>
        <time_frame>Within 31 days (day 0-30) after vaccination</time_frame>
        <population>Analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix and Tritanrix-HepB/Hib Group</title>
            <description>Subjects received SynflorixTM (GSK1024850A) intramuscularly in the right thigh co-administered with TritanrixTM-HepB/Hib intramuscularly in the left thigh at 6-10-14 weeks of age (=study month 0, 1, 2)</description>
          </group>
          <group group_id="O2">
            <title>Hiberix Group and Tritanrix-HepB Group</title>
            <description>Subjects received HiberixTM intramuscularly in the right thigh co-administered with TritanrixTM-HepB intramuscularly in the left thigh at 6-10-14 weeks of age (=study month 0, 1, 2)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Unsolicited Adverse Events (AEs)</title>
          <description>An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms</description>
          <population>Analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="240"/>
                <count group_id="O2" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Serious Adverse Events (SAEs)</title>
        <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
        <time_frame>Following first vaccination (Month 0) throughout the entire study period (month 3)</time_frame>
        <population>Analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix and Tritanrix-HepB/Hib Group</title>
            <description>Subjects received SynflorixTM (GSK1024850A) intramuscularly in the right thigh co-administered with TritanrixTM-HepB/Hib intramuscularly in the left thigh at 6-10-14 weeks of age (=study month 0, 1, 2)</description>
          </group>
          <group group_id="O2">
            <title>Hiberix Group and Tritanrix-HepB Group</title>
            <description>Subjects received HiberixTM intramuscularly in the right thigh co-administered with TritanrixTM-HepB intramuscularly in the left thigh at 6-10-14 weeks of age (=study month 0, 1, 2)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Serious Adverse Events (SAEs)</title>
          <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
          <population>Analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="240"/>
                <count group_id="O2" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>For other AEs day 0-3 (solicited) and day 0-30 unsolcited. For SAEs month 0 to Month 3.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Synflorix and Tritanrix-HepB/Hib Group</title>
          <description>Subjects received SynflorixTM (GSK1024850A) intramuscularly in the right thigh co-administered with TritanrixTM-HepB/Hib intramuscularly in the left thigh at 6-10-14 weeks of age (=study month 0, 1, 2)</description>
        </group>
        <group group_id="E2">
          <title>Hiberix Group and Tritanrix-HepB Group</title>
          <description>Subjects received HiberixTM intramuscularly in the right thigh co-administered with TritanrixTM-HepB intramuscularly in the left thigh at 6-10-14 weeks of age (=study month 0, 1, 2)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Hypochromic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Chikungunya virus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="209" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="105" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="209" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="105" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Redness</sub_title>
                <counts group_id="E1" subjects_affected="128" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="76" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" subjects_affected="166" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="83" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Drowsiness</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="182" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="85" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="178" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="88" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Loss of appetite</sub_title>
                <counts group_id="E1" subjects_affected="96" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Rhinitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

